# cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer

> **NCT07224815** · — · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 600 (estimated)

## Conditions studied

- CRC (Colorectal Cancer)

## Interventions

- **DIAGNOSTIC_TEST:** cfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase)
- **DIAGNOSTIC_TEST:** EpiCORE Assay (Targeted Sequencing / qPCR Validation)

## Key facts

- **NCT ID:** NCT07224815
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-21
- **Primary completion:** 2026-06-18
- **Final completion:** 2026-06-18
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224815, "cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07224815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*